Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Fox

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
British Journal of Cancer|January 24, 2009
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapyE Y Tan, M Yan, L Campo, et al.
Breast (Edinburgh, Scotland)|July 19, 2016
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancerD Andreis, S Bonardi, G Allevi, et al.
Cell Death & Disease|July 17, 2015
Targeting Mdmx to treat breast cancers with wild-type p53S Haupt, D Buckley, J-M B Pang, et al.
British Journal of Cancer|December 3, 2014
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancerL Bazzola, C Foroni, D Andreis, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
British Journal of Cancer|January 24, 2009
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapyE Y Tan, M Yan, L Campo, et al.
Breast (Edinburgh, Scotland)|July 19, 2016
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancerD Andreis, S Bonardi, G Allevi, et al.
Cell Death & Disease|July 17, 2015
Targeting Mdmx to treat breast cancers with wild-type p53S Haupt, D Buckley, J-M B Pang, et al.
British Journal of Cancer|December 3, 2014
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancerL Bazzola, C Foroni, D Andreis, et al.
Pageof 9